Table 2.
Patient and tumor characteristics
| Total breasts treated (patients) | 41 (40) |
|---|---|
| Age (years) | |
| Median | 60 |
| Range | 53-78 |
| Side | |
| Left | 26 (63%) |
| Right | 15 (37%) |
| Histology | |
| IDC and DCIS/extensive DCIS | 27 (66%)/7 (17%) |
| IDC | 6 (15%) |
| DCIS | 6 (15%) |
| ILC | 1 (2%) |
| ILC and DCIS | 1 (2%) |
| Grade | |
| 1 | 16 (39%) |
| 2 | 20 (49%) |
| 3 | 5 (12%) |
| LVI | |
| Yes | 1 (2%) |
| No | 40 (98%) |
| T size (mm) | |
| Median | 5 |
| Range | 1-25 |
| Quadrant | |
| Upper outer | 25 (61%) |
| Upper inner | 6 (15%) |
| Lower outer | 6 (15%) |
| Lower inner | 3 (7%) |
| Central | 1 (2%) |
| Margins (mm) | |
| >2 | 37 (90%) |
| 1-2 | 3 (7%) |
| > 0, < 1 | 0 (0%) |
| 0 | 1 (2%) |
| Receptors | |
| Invasive ER+/HER2- | 32 (78%) |
| Invasive ER+/HER2+ | 2 (5%) |
| Invasive ER+/HER2 unknown | 1 (2%) |
| DCIS ER+ | 5 (12%) |
| DCIS unknown | 1 (2%) |
| Oncotype (n = 22) | |
| Median | 11 |
| Range | 0-22 |
| Chemotherapy | |
| None | 40 (98%) |
| Docetaxel/cyclophosphamide | 1 (2%) |
| Hormone therapy | |
| AI | 24 (59%) |
| Tamoxifen | 3 (7%) |
| Tamoxifen/AI combination | 1 (2%) |
| None | 13 (32%) |
Abbreviation: AI = aromatase inhibitor; DCIS = ductal carcinoma in situ; IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; LVI = lymphovascular space invasion.